Replimune Group, Inc. (NASDAQ:REPL) Receives Average Rating of “Buy” from Brokerages

Shares of Replimune Group, Inc. (NASDAQ:REPL) have earned a consensus rating of “Buy” from the eight ratings firms that are covering the firm, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $19.14.

Several equities research analysts recently issued reports on the stock. BMO Capital Markets raised their target price on shares of Replimune Group from $18.00 to $27.00 and gave the stock an “outperform” rating in a research report on Wednesday. Jefferies Financial Group lifted their price target on shares of Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, December 4th. Finally, HC Wainwright upped their price objective on Replimune Group from $17.00 to $21.00 and gave the stock a “buy” rating in a report on Wednesday.

Insider Activity at Replimune Group

In related news, insider Konstantinos Xynos sold 7,246 shares of the firm’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $10.78, for a total transaction of $78,111.88. Following the sale, the insider now directly owns 109,885 shares in the company, valued at approximately $1,184,560.30. This trade represents a 6.19 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Sushil Patel sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $12.42, for a total value of $124,200.00. Following the completion of the transaction, the chief executive officer now owns 202,014 shares of the company’s stock, valued at approximately $2,509,013.88. This represents a 4.72 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 8.80% of the company’s stock.

Institutional Trading of Replimune Group

A number of hedge funds have recently made changes to their positions in REPL. Point72 DIFC Ltd acquired a new stake in Replimune Group during the 2nd quarter valued at $57,000. Erste Asset Management GmbH acquired a new stake in shares of Replimune Group during the third quarter valued at about $133,000. China Universal Asset Management Co. Ltd. increased its position in shares of Replimune Group by 82.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 13,140 shares of the company’s stock worth $144,000 after acquiring an additional 5,926 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in shares of Replimune Group by 81.7% in the third quarter. BNP Paribas Financial Markets now owns 15,011 shares of the company’s stock worth $165,000 after acquiring an additional 6,748 shares in the last quarter. Finally, GSA Capital Partners LLP purchased a new position in Replimune Group in the third quarter valued at about $222,000. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Replimune Group Trading Down 1.2 %

Shares of REPL opened at $13.59 on Friday. Replimune Group has a fifty-two week low of $4.92 and a fifty-two week high of $17.00. The company has a market capitalization of $929.79 million, a PE ratio of -4.46 and a beta of 1.28. The stock has a fifty day moving average of $12.28 and a two-hundred day moving average of $11.35. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11.

Replimune Group (NASDAQ:REPL) last released its earnings results on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.07. As a group, analysts forecast that Replimune Group will post -2.88 EPS for the current year.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.